Nicholas S. Downing

2.9k total citations · 1 hit paper
46 papers, 1.9k citations indexed

About

Nicholas S. Downing is a scholar working on Economics and Econometrics, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, Nicholas S. Downing has authored 46 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Economics and Econometrics, 10 papers in Cardiology and Cardiovascular Medicine and 10 papers in Pharmacology. Recurrent topics in Nicholas S. Downing's work include Health Systems, Economic Evaluations, Quality of Life (20 papers), Pharmaceutical Economics and Policy (16 papers) and Pharmaceutical industry and healthcare (10 papers). Nicholas S. Downing is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (20 papers), Pharmaceutical Economics and Policy (16 papers) and Pharmaceutical industry and healthcare (10 papers). Nicholas S. Downing collaborates with scholars based in United States, China and France. Nicholas S. Downing's co-authors include Harlan M. Krumholz, Joseph S. Ross, Nilay D. Shah, Jenerius A. Aminawung, Kumar Dharmarajan, Emily M. Bucholz, Sahand Negahban, Ajay Manhapra, Bobak J. Mortazavi and Shu-Xia Li and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Nicholas S. Downing

45 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012

2014 301 citations Nicholas S. Downing, Jenerius A. Aminawung et al. profile →

Peers

Countries citing papers authored by Nicholas S. Downing

Since Specialization

Citations

This map shows the geographic impact of Nicholas S. Downing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas S. Downing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas S. Downing more than expected).

Fields of papers citing papers by Nicholas S. Downing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas S. Downing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas S. Downing. The network helps show where Nicholas S. Downing may publish in the future.

Co-authorship network of co-authors of Nicholas S. Downing

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas S. Downing. A scholar is included among the top collaborators of Nicholas S. Downing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas S. Downing. Nicholas S. Downing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Missing value imputation in environmental, social, and governance data: an impact on emissions scores 2025 ·Finance research letters ·Nicholas S. Downing	0
2	Use of intravenous magnesium sulfate among patients with acute myocardial infarction in China from 2001 to 2015: China PEACE—Retrospective AMI Study 2020 ·BMJ Open ·Xianqiang Wang, Xue Du, Hao Yang, Emily M. Bucholz, Nicholas S. Downing, John A. Spertus, Fredrick A. Masoudi, Jing Li, (unknown), Yan Gao, Shuang Hu, Xueke Bai, Harlan M. Krumholz, Xi Li	4
3	Describing the performance of U.S. hospitals by applying big data analytics 2017 ·PLoS ONE ·Nicholas S. Downing, Alexander Cloninger, Arjun K. Venkatesh, (unknown), Elizabeth E. Drye, Ronald R. Coifman, Harlan M. Krumholz	12
4	Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study 2017 ·BMJ Open ·(unknown), Nicholas S. Downing, Joseph S. Ross, Frank David	10
5	Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review 2017 ·BMJ ·(unknown), Harlan M. Krumholz, Nicholas S. Downing, Jenerius A. Aminawung, Nilay D. Shah, Joseph S. Ross	83
6	Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes 2017 ·Chinese Medical Journal ·(unknown), Karthik Murugiah, Na Li, Xi Li, Zihui Xu, Jing Li, Cheng Chen, Hong Mao, Nicholas S. Downing, Harlan M. Krumholz, Lixin Jiang	16
7	Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot 2016 ·BMJ Open ·Jiapeng Lu, (unknown), Nicholas S. Downing, Chaoqun Wu, Li Li, Harlan M. Krumholz, Lixin Jiang	92
8	Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals 2016 ·Trials ·Nicholas S. Downing, Nilay D. Shah, (unknown), Jenerius A. Aminawung, Harlan M. Krumholz, Joseph S. Ross	57
9	National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011 2016 ·PLoS ONE ·Lihua Zhang, Jing Li, Xi Li, Khurram Nasir, Haibo Zhang, Yongjian Wu, Shuang Hu, Qing Wang, Nicholas S. Downing, Nihar R. Desai, Frederick A. Masoudi, John A. Spertus, Harlan M. Krumholz, Lixin Jiang, (unknown)	11
10	Qingdao Port Cardiovascular Health Study: a prospective cohort study 2015 ·BMJ Open ·Erica S. Spatz, Xianyan Jiang, Jiapeng Lu, Frederick A. Masoudi, John A. Spertus, Yongfei Wang, Xi Li, Nicholas S. Downing, Khurram Nasir, Xue Du, Jing Li, Harlan M. Krumholz, Xiancheng Liu, Lixin Jiang	4
11	Organizational culture in cardiovascular care in Chinese hospitals: a descriptive cross-sectional study 2015 ·BMC Health Services Research ·Emily S. Yin, Nicholas S. Downing, Xi Li, Sara J. Singer, Leslie Curry, Jing Li, Harlan M. Krumholz, Lixin Jiang	7
12	China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction 2015 ·Chinese Medical Journal ·Jing Li, Rachel P. Dreyer, Xi Li, Xue Du, Nicholas S. Downing, (unknown), Haibo Zhang, Fang Feng, (unknown), Xiao Xu, Shu‐Xia Li, Zhenqiu Lin, Frederick A. Masoudi, John A. Spertus, Harlan M. Krumholz, Lixin Jiang	18
13	10 year trends in urban–rural disparities in treatments and outcomes after ST-elevation myocardial infarction in China: insights from the China PEACE-Retrospective Acute Myocardial Infarction Study 2015 ·The Lancet ·Xi Li, Karthik Murugiah, Jing Li, Qing Wang, Shuang Hu, Frederick A. Masoudi, John A. Spertus, Nicholas S. Downing, Paul S. Chan, Harlan M. Krumholz, Lixin Jiang	3
14	Characterizing the US FDA's approach to promoting transformative innovation 2015 ·Nature Reviews Drug Discovery ·Nicholas S. Downing, Harlan M. Krumholz, Joseph S. Ross, Nilay D. Shah	11
15	Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New Drugs 2015 ·Health Affairs ·Joseph S. Ross, Kristina Dzara, Nicholas S. Downing	17
16	Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study 2015 ·Pharmacoepidemiology and Drug Safety ·Jean‐David Zeitoun, Jérémie H. Lefèvre, Nicholas S. Downing, Henri Bergeron, Joseph S. Ross	9
17	Inconsistencies among European Union Pharmaceutical Regulator Safety Communications: A Cross-Country Comparison 2014 ·PLoS ONE ·Jean‐David Zeitoun, Jérémie H. Lefèvre, Nicholas S. Downing, Henri Bergeron, Joseph S. Ross	30
18	Publication of Pivotal Efficacy Trials for Novel Therapeutic Agents Approved Between 2005 and 2011 2014 ·JAMA Internal Medicine ·James W. Smithy, Nicholas S. Downing, Joseph S. Ross	14
19	Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies 2012 ·New England Journal of Medicine ·Nicholas S. Downing, Jenerius A. Aminawung, Nilay D. Shah, Joel B. Braunstein, Harlan M. Krumholz, Joseph S. Ross	125
20	Avoidance of Generic Competition by Abbott Laboratories' Fenofibrate Franchise 2012 ·Archives of Internal Medicine ·Nicholas S. Downing	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact